Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия Здоровые добровольцы

A(H5N1) inactivated influenza vaccine (IIV); A(H5N2) live attenuated influenza vaccine (LAIV)

Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects

Номер протоколаLAIV-H5N2-02
ФазаФаза II
Участников по плану — во всех странах исследования43
Сроки01.05.2014 — 01.09.2014
Начало: 1 мая 2014Окончание: 1 сентября 2014
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02153671/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • В исследовании участвуют здоровые добровольцы.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–51 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 43 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.
  • Плановая дата окончания (09.2014) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–51 лет
ПолЛюбой
Здоровые добровольцыпринимаются

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 26

Критерии включения

  • Legal male or female adult 18 through 51 years of age at the enrollment visit
  • Literate and willing to provide written informed consent
  • A signed informed consent
  • Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination
  • Capable and willing to complete a memory aid and willing to return for all follow-up visits
  • For females, willing to take reliable birth control measures through Day 56

Критерии невключения

  • Participation in another clinical trial involving any investigational agent within the previous three months or planned enrollment in such a trial during the period of this study
  • Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt
  • Participation in any other clinical trials involving any H5-matched influenza vaccines except that in Protocol LAIV-H5N2-01
  • Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever
  • Other acute illness at the time of study enrollment
  • Receipt of immunoglobulin or other blood products within three months prior to study enrollment or planned receipt during study period
  • Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants and/or immune-modulating therapy within six months prior to study enrollment
  • History of bronchial asthma
  • Hypersensitivity after previous administration of any (not only influenza) vaccines.
  • Other adverse event (AE) following immunization at least possibly related to previous receipt of any (not only influenza) vaccine
  • Suspected or known hypersensitivity to any of the study vaccine components, including protein of chicken eggs
  • Seasonal (autumnal) hypersensitivity to the natural environment
  • Acute or chronic clinically significant abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale will be excluded from entry into the study
  • History of leukemia or any other blood diseases or solid organ cancer
  • History of thrombocytopenic purpura or known bleeding disorder
  • History of seizures
  • Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection
  • Known chronic hepatitis B virus (HBV) or hepatitis C (HCV) infection
  • Known tuberculosis infection or evidence of previous tuberculosis exposure
  • History of chronic alcohol abuse and/or illegal drug use
  • Pregnancy or lactation.
  • Systemic connective tissue disorders
  • Adrenal gland diseases
  • Hereditary, degenerative and progredient diseases of the nervous system
  • Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives
  • Allergic, including anaphylactic, reactions to any (not only influenza) vaccines

Источник: ClinicalTrials.gov, NCT02153671 · запись обновлена в реестре 18 февраля 2019.

Дизайн и результаты

ДизайнНерандомизированное, открытое (без ослепления), параллельные группы; цель — профилактика
Включено участников (факт, все страны)43
Что измеряют — первичные конечные точки (10), вторичных — 8
  • Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Turkey/Turkey/05/133 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/Indonesia/5/2005 (H5N1) PR8-based Candidate Vaccine Virus Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/Turkey/Turkey/5/05(H5N1) PR8-based Candidate Vaccine Virus Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Geometric Mean Titer of Microneutralization Antibody Response to A/17/Turkey/Turkey/05/133 (H5N2) (17/t/Tur (H5N2)) LAIV Strain Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Geometric Mean Titer of Microneutralization Antibody Response to A/Indonesia/5/2005 (H5N1) PR8-based Candidate Vaccine Virus Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Number and Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI) Antibody Against 17/t/Tur (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Number and Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI) Antibody Against A/Turkey/Turkey/5/05 (H5N1) PR8-based Candidate Vaccine Virus Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Number and Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI) Antibody Against A/Indonesia/5/2005 (H5N1) PR8-based Candidate Vaccine Virus Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days
  • Number and Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI) Antibody Against A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated Influenza Vaccine (IIV) — 56 days

Цель исследования

This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects previously primed with LAIV and subjects who did not received LAIV.

Где проходит

1 центр в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02153671 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.